

ORGANIZED BY:

Department of Medical
and Surgical Sciences (DIMEC)
Alma Mater Studiorum
University of Bologna, Italy

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Aurora-CO, USA

NOVEMBER
13TH-14TH
2018

BOLOGNA
(ITALY)

INTERNATIONAL SYMPOSIUM ON:

URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

With an
unrestricted grant by



FONDAZIONE
INTERNAZIONALE
MENARINI

TUESDAY, NOVEMBER 13TH, 2018 – MORNING
Salone del Podestà - Palazzo Re Enzo

SESSION III – UPDATE ON THE CLINICAL EVIDENCE: URIC ACID, METABOLIC AND RENAL DISEASE

WEDNESDAY, NOVEMBER 14TH, 2018 – AFTERNOON
Salone del Podestà - Palazzo Re Enzo

SESSION I – THE CARDIO-METABOLIC BURDEN IN PATIENTS WITH GOUT

09.00 a.m.	Introduction to the meeting objectives C. Borghi (Bologna, I)
Chairpersons: E. Agabiti Rosei (Brescia, I) T. Gibson (London, UK)	
09.20 a.m.	F. M. Galassi (Adelaide, AU) Uric acid and gout: tales from the Ancient World
09.40 a.m.	L. Punzi (Padua, I) The cardio-metabolic involvement in gout. The position of guidelines
10.00 a.m.	D. Rothenbacher (Ulm, D) How can we quantify the cardio-metabolic risk in patients with gout? An epidemiological perspective
10.20 a.m.	M. Andrés (Alicante, S) The management of cardio-metabolic risk in patients with gout
10.40 a.m.	M. M. Givertz (Boston-MA, USA) Treating gout in patients with cardiovascular disease
11.00 a.m.	General discussion
11.30 a.m.	Coffee break
Main Lecture	
12.00 p.m.	Introduction: E. Ambrosioni (Bologna, I), M. H. Alderman (New York-NY, USA) R. J. Johnson (Aurora-CO, USA) From Uric acid to cardio-metabolic disease: can we identify the patients at risk?
01.00 p.m.	Lunch

Chairpersons:	M. Burnier (Lausanne, CH) C. Borghi (Bologna, I)
04.10 p.m.	D. H. Kang (Seoul, K) Uric acid and new-onset metabolic syndrome
04.30 p.m.	M. Kuwabara (Tokyo, J) The interaction between uric acid and lipid profile
04.50 p.m.	R. Pontremoli (Genoa, I) Uric acid and renal dysfunction: what is the egg?
05.10 p.m.	R. Cifkova (Prague, CZ) Uric acid, pregnancy and cardio-renal disease
05.30 p.m.	General discussion
06.00 p.m.	Conclusion and end of the sessions

WEDNESDAY, NOVEMBER 14TH, 2018 – MORNING
Salone del Podestà - Palazzo Re Enzo

08.30 a.m.	Introduction to the meeting objectives C. Borghi (Bologna, I)
------------	---

SESSION IV – QUANTIFICATION OF CARDIO-METABOLIC RISK IN PATIENTS WITH HYPERURICEMIA

Chairpersons:	G. Mancia (Milan, I) A. J. Manolis (Athens, GR)
09.00 a.m.	G. Desideri (L'Aquila, I) Is the determination of serum uric acid enough?
09.20 a.m.	T. R. Merriman (Dunedin, NZ) Is genetic profile useful for clinical practice?
09.40 a.m.	J. Dawson (Glasgow, UK) Is genetic approach the right solution?
10.00 a.m.	M. Burnier (Lausanne, CH) Is the measure of xanthine-oxidase a reliable tool?
10.20 a.m.	L. Scheepers , (Gothenborg, SE) Is it reasonable to consider a functional index?
10.40 a.m.	General discussion
11.00 a.m.	Coffee break

SESSION VI – HYPERURICEMIA AND CARDIO-METABOLIC RISK: WHO IS TO TREAT?

Chairpersons:	S. Taddei (Pisa, I) A. Manolis (Athens, GR)
02.00 p.m.	P. M. Nilsson (Malmo, SE) SGLT-2 inhibitors and control of uric acid: mechanism and potential advantages
02.20 p.m.	J. George (Dundee, UK) Urate lowering drugs and prevention of cardiometabolic disease: the evidence
02.40 p.m.	S. Masi (Pisa, I) Recent evidence in cardiorenal protection with Urate Lowering Treatment
03.00 p.m.	A. Stack (Limerick, IRL) Is there any "J-shaped" curve for serum uric acid?
03.20 p.m.	C. Borghi (Bologna, I) Hyperuricemia and cardiometabolic disease: the role of renal impairment
03.40 p.m.	A. D. Struthers (Dundee, UK) The treatment of asymptomatic hyperuricemia: who, when and why
04.00 p.m.	L. G. Sanchez-Lozada (Mexico City, MEX) The non-pharmacologic approach to hyperuricemia. Solutions beyond diet
04.20 p.m.	J. T. Kielstein (Braunschweig, D) How to investigate the cardiovascular and renal effects of urate-lowering drugs?
04.40 p.m.	General discussion
05.10 p.m.	Closing Remarks and end of the Symposium

GENERAL INFORMATION

MEETING VENUE
The venue for the Meeting is **Salone del Podestà, Palazzo Re Enzo** - Piazza del Nettuno, 1 - Bologna

SECRETARIAT DESK DURING THE MEETING
The Secretariat desk is open at the following times:
Tuesday, November 13th, from 07.30 a.m. to 06.00 p.m.
Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

OFFICIAL LANGUAGE
The official language of the Meeting is English.

REGISTRATION
The Meeting is free to attend. The registration link is available on the website www.iejc-srl.it
Please register **within October 20, 2018**.

LUNCHES AND COFFEE BREAKS
Lunches and coffee breaks are served in the Congress area.

ABSTRACTS BOOK
Participants can get the Abstract book at the Symposium.

CERTIFICATE OF ATTENDANCE
The certificate of attendance is available, on request, at the end of the Meeting at the Secretariat desk.

CME CREDITS
EACCME and EBAC Credits have been requested for physicians for the following disciplines: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.
Italian CME credits
Provider Italian CME Credits: I&C srl 5387 (event number 240472)
Number of credits: 4,2
I&C srl is responsible for the content, the quality and the ethical honesty of the CME activity.
The meeting is accredited for the following specialties: Nurse, Pharmacist, Biologist, Physician and Surgeon (Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene). The physicians belonging to other disciplines will not get the credits.
The attendance to the meeting is partially on sponsor companies invitation.

METHODOLOGY: Residential
COURSE OBJECTIVES: Clinical, Diagnostic, Therapy, Treatment Path
In order to obtain CME credits, it is mandatory for participants to attend 90% of the course (both days) and to complete CME procedures online: learners' feedback form and educational needs form. Instructions are provided on site.

TUESDAY, NOVEMBER 13TH, 2018 – AFTERNOON
Salone del Podestà - Palazzo Re Enzo

SESSION II – UPDATE ON THE CLINICAL EVIDENCE: URIC ACID AND CARDIOVASCULAR DISEASE

Chairpersons:	P. Palatini (Padua, I) J. Redon (Valencia, S)
02.00 p.m.	A. Viridis (Pisa, I) Uric acid and blood pressure
02.20 p.m.	S. G. Wannamethee (London, UK) Uric acid, left ventricular function and heart failure
02.40 p.m.	G. Ambrosio (Perugia, I) Uric acid and coronary artery disease
03.00 p.m.	K. Tsioufis (Athens, GR) Uric acid and atrial fibrillation
03.20 p.m.	General discussion
03.40 p.m.	Coffee break

SESSION V – PREVENTION OF CARDIO-METABOLIC RISK IN PATIENTS WITH HYPERURICEMIA

Chairpersons:	M. L. Muesan (Brescia, I) K. Narkiewicz (Gdansk, P)
11.30 a.m.	E. Lurbe (Valencia, S) Age-dependent prevention of hyperuricemia: the earlier is the better?
11.50 a.m.	D. I. Feig (Birmingham-AL, USA) The role of fructose consumption and dietary approach
12.10 a.m.	G. Grassi (Milan, I) The management of additional risk factors in patients with hyperuricemia
12.30 p.m.	C. Ferri (L'Aquila, I) Is drug-induced hyperuricemia a cardio-metabolic risk factor?
12.50 p.m.	General discussion
01.00 p.m.	Lunch